quetiapine lambda 200 mg depottablett
lambda therapeutics limited - kvetiapinfumarat - depottablett - 200 mg - kvetiapinfumarat 230,3 mg aktiv substans; laktosmonohydrat hjälpämne - kvetiapin
quetiapine lambda 300 mg depottablett
lambda therapeutics limited - kvetiapinfumarat - depottablett - 300 mg - kvetiapinfumarat 345,45 mg aktiv substans; laktosmonohydrat hjälpämne - kvetiapin
quetiapine lambda 400 mg depottablett
lambda therapeutics limited - kvetiapinfumarat - depottablett - 400 mg - kvetiapinfumarat 460,6 mg aktiv substans; laktosmonohydrat hjälpämne - kvetiapin
lambdastatin 10 mg filmdragerad tablett
biokanol pharma gmbh - atorvastatinkalcium, amorft - filmdragerad tablett - 10 mg - atorvastatinkalcium, amorft 10,363 mg aktiv substans - atorvastatin
lambdastatin 20 mg filmdragerad tablett
biokanol pharma gmbh - atorvastatinkalcium, amorft - filmdragerad tablett - 20 mg - atorvastatinkalcium, amorft 20,725 mg aktiv substans - atorvastatin
lambdastatin 40 mg filmdragerad tablett
biokanol pharma gmbh - atorvastatinkalcium, amorft - filmdragerad tablett - 40 mg - atorvastatinkalcium, amorft 41,45 mg aktiv substans - atorvastatin
lambdastatin 80 mg filmdragerad tablett
biokanol pharma gmbh - atorvastatinkalcium, amorft - filmdragerad tablett - 80 mg - atorvastatinkalcium, amorft 82,9 mg aktiv substans - atorvastatin
veklury
gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - immunförsvaret sera och immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 och 5.